Diagnostics
An expert in the application of artificial intelligence in precision medicine, Christophe Béesau’s appointment will allow Metafora to step up its efforts in oncology and immunology
Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease.
Researchers have hunted for years to find a commonality across all cancers, a so-called “silver bullet” that ties them all together. Researchers from the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology have identified a nano-scaled DNA signature that seems to be common to all cancers. This has the potential to be used as an early cancer detection test, what is often called a liquid biopsy.
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.
an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients) and show a favorable and distinct treatment strategy for the low and high-risk patients in an interim data analysis.
MDxHealth SA today announces that the New York State Department of Health has approved its SelectMDx test for Prostate Cancer.
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
DCN Dx and QIAGEN Lake Constance announced today that Rapid Pathogen Screening, Inc. (RPS) was the winner of the first $10,000 Innovation Award at the Advanced Lateral Flow Course.
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products
Epigenomics AG today announced its financial results for the third quarter and the nine months 2018 ending September 30.
PRESS RELEASES